484 related articles for article (PubMed ID: 15504864)
1. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
2. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
3. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
5. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
Melikyan GB; Egelhofer M; von Laer D
J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
[TBL] [Abstract][Full Text] [Related]
6. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
7. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
8. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
[TBL] [Abstract][Full Text] [Related]
10. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
Liu S; Lu H; Zhao Q; He Y; Niu J; Debnath AK; Wu S; Jiang S
Biochim Biophys Acta; 2005 May; 1723(1-3):270-81. PubMed ID: 15823507
[TBL] [Abstract][Full Text] [Related]
11. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
Liu S; Jiang S
Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
[TBL] [Abstract][Full Text] [Related]
12. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
13. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
He Y; Liu S; Jing W; Lu H; Cai D; Chin DJ; Debnath AK; Kirchhoff F; Jiang S
J Biol Chem; 2007 Aug; 282(35):25631-9. PubMed ID: 17616522
[TBL] [Abstract][Full Text] [Related]
14. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
15. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.
Liu K; Lu H; Hou L; Qi Z; Teixeira C; Barbault F; Fan BT; Liu S; Jiang S; Xie L
J Med Chem; 2008 Dec; 51(24):7843-54. PubMed ID: 19053778
[TBL] [Abstract][Full Text] [Related]
17. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
Mo H; Konstantinidis AK; Stewart KD; Dekhtyar T; Ng T; Swift K; Matayoshi ED; Kati W; Kohlbrenner W; Molla A
Virology; 2004 Nov; 329(2):319-27. PubMed ID: 15518811
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Abo-Dya NE; Avan I; Gyanda K; Lu L; Katritzky AR; Debnath AK
J Med Chem; 2011 Jan; 54(2):572-9. PubMed ID: 21190369
[TBL] [Abstract][Full Text] [Related]
19. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
20. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41.
Zhao Q; Ernst JT; Hamilton AD; Debnath AK; Jiang S
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):989-97. PubMed ID: 12396451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
